Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

263 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study.
Balar AV, Kamat AM, Kulkarni GS, Uchio EM, Boormans JL, Roumiguié M, Krieger LEM, Singer EA, Bajorin DF, Grivas P, Seo HK, Nishiyama H, Konety BR, Li H, Nam K, Kapadia E, Frenkl T, de Wit R. Balar AV, et al. Among authors: roumiguie m. Lancet Oncol. 2021 Jul;22(7):919-930. doi: 10.1016/S1470-2045(21)00147-9. Epub 2021 May 26. Lancet Oncol. 2021. PMID: 34051177 Clinical Trial.
Comparison of the prognosis of primary vs. progressive muscle invasive bladder cancer after radical cystectomy: Results from a large multicenter study.
Nouhaud FX, Chakroun M, Lenormand C, Ouzaid I, Peyronnet B, Gryn A, Prudhomme T, Grafeille V, Soulié M, Roumiguié M, Verhoest G, Xylinas E, Bouzouita A, Chebil M, Pfister C. Nouhaud FX, et al. Among authors: roumiguie m. Urol Oncol. 2021 Mar;39(3):195.e1-195.e6. doi: 10.1016/j.urolonc.2020.09.006. Epub 2020 Nov 16. Urol Oncol. 2021. PMID: 33214030
International Bladder Cancer Group Consensus Statement on Clinical Trial Design for Patients with Bacillus Calmette-Guérin-exposed High-risk Non-muscle-invasive Bladder Cancer.
Roumiguié M, Kamat AM, Bivalacqua TJ, Lerner SP, Kassouf W, Böhle A, Brausi M, Buckley R, Persad R, Colombel M, Lamm D, Palou-Redorta J, Soloway M, Brothers K, Steinberg G, Lotan Y, Sylvester R, Alfred Witjes J, Black PC. Roumiguié M, et al. Eur Urol. 2022 Jul;82(1):34-46. doi: 10.1016/j.eururo.2021.12.005. Epub 2021 Dec 23. Eur Urol. 2022. PMID: 34955291 Review.
[Guidelines from the cancer committee of the French Association of Urology (CC-AFU) for adequate intravesical instillations of Mitomycin C, Epirubicin, and BCG for non-muscle invasive bladder cancer].
Leon P, Saint F, Audenet F, Roumiguié M, Allory Y, Loriot Y, Masson-Lecomte A, Pradère B, Seisen T, Traxer O, Xylinas E, Roupret M, Neuzillet Y. Leon P, et al. Among authors: roumiguie m. Prog Urol. 2022 Apr;32(5):299-311. doi: 10.1016/j.purol.2022.01.004. Epub 2022 Feb 9. Prog Urol. 2022. PMID: 35151545 French.
Immediate radical cystectomy versus BCG immunotherapy for T1 high-grade non-muscle-invasive squamous bladder cancer: an international multi-centre collaboration.
Lonati C, Afferi L, Mari A, Minervini A, Krajewski W, Borghesi M, Schulz GB, Rink M, Montorsi F, Briganti A, Colombo R, Martini A, Necchi A, Contieri R, Hurle R, Umari P, Zamboni S, Simeone C, Soria F, Marra G, Gontero P, Teoh JY, Klatte T, Bajeot AS, Roumiguié M, Rouprêt M, Masson-Lecomte A, Laukhtina E, Valiquette AS, Mir MC, Antonelli A, Einerhand SMH, Hendricksen K, Carando R, Fankhauser CD, Baumeister P, Mattei A, Shariat SF, Moschini M; European Association of Urology—Young Academic Urologists (EAU-YAU): Urothelial Carcinoma Working Group. Lonati C, et al. Among authors: roumiguie m. World J Urol. 2022 May;40(5):1167-1174. doi: 10.1007/s00345-022-03958-9. Epub 2022 Feb 26. World J Urol. 2022. PMID: 35218372
[ypT0N0 after neoadjuvant chemotherapy and cystectomy for muscle-invasive bladder cancer: Incidence and prognosis. A review from the Bladder group of the French Committee of Oncology].
Pignot G, Houédé N, Roumiguié M, Audenet F, Brunelle S, Colin P, Compérat E, Larré S, Masson-Lecomte A, Neuzillet Y, Xylinas E, Méjean A, Rouprêt M; les membres du CCAFU Vessie. Pignot G, et al. Among authors: roumiguie m. Prog Urol. 2018 Oct;28(12):567-574. doi: 10.1016/j.purol.2018.07.003. Epub 2018 Sep 8. Prog Urol. 2018. PMID: 30205925 Review. French.
PD-L1 expression and pattern of immune cells in pre-treatment specimens are associated with disease-free survival for HR-NMIBC undergoing BCG treatment.
Roumiguié M, Compérat E, Chaltiel L, Nouhaud FX, Verhoest G, Masson-Lecomte A, Colin P, Audenet F, Houédé N, Larré S, Xylinas E, Brunelle S, Piana-Thomassin J, Cotte J, Pignot G, Neuzillet Y, Rouprêt M. Roumiguié M, et al. World J Urol. 2021 Nov;39(11):4055-4065. doi: 10.1007/s00345-020-03329-2. Epub 2020 Jul 14. World J Urol. 2021. PMID: 32666225
263 results